In Non-clinical Cancer Studies Senesco Technologies, Inc. (SNT)’s Therapeutic Candidate, SNS01-T, Works Synergistically In Combination With The Active Components Of Revlimid® And Velcade®
3/4/2014 8:47:37 AM
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) announced the publication in the peer-reviewed journal Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy, of new results from placebo-controlled, non-clinical studies of its therapeutic candidate, SNS01-T, in models of B-cell cancers that show synergy in combination with the active components of Revlimid and Velcade.
Help employers find you! Check out all the jobs and post your resume.
comments powered by